These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
620 related articles for article (PubMed ID: 26922358)
1. Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis. Iannone A; Losurdo G; Pricci M; Girardi B; Massaro A; Principi M; Barone M; Ierardi E; Di Leo A J Gastrointest Cancer; 2016 Jun; 47(2):143-51. PubMed ID: 26922358 [TBL] [Abstract][Full Text] [Related]
2. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Lidgard GP; Domanico MJ; Bruinsma JJ; Light J; Gagrat ZD; Oldham-Haltom RL; Fourrier KD; Allawi H; Yab TC; Taylor WR; Simonson JA; Devens M; Heigh RI; Ahlquist DA; Berger BM Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1313-8. PubMed ID: 23639600 [TBL] [Abstract][Full Text] [Related]
3. Colorectal Cancer Screening With Traditional and New-generation Fecal Immunochemical Tests: A Critical Review of Fecal Occult Blood Tests. Meklin J; Syrjänen K; Eskelinen M Anticancer Res; 2020 Feb; 40(2):575-581. PubMed ID: 32014898 [TBL] [Abstract][Full Text] [Related]
4. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). Heigh RI; Yab TC; Taylor WR; Hussain FT; Smyrk TC; Mahoney DW; Domanico MJ; Berger BM; Lidgard GP; Ahlquist DA PLoS One; 2014; 9(1):e85659. PubMed ID: 24465639 [TBL] [Abstract][Full Text] [Related]
5. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening. Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667 [TBL] [Abstract][Full Text] [Related]
6. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test. Dollinger MM; Behl S; Fleig WE Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540 [TBL] [Abstract][Full Text] [Related]
7. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults. Sharma T Public Health; 2020 May; 182():70-76. PubMed ID: 32179290 [TBL] [Abstract][Full Text] [Related]
8. Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests. Meklin J; SyrjÄnen K; Eskelinen M Anticancer Res; 2020 Jul; 40(7):3591-3604. PubMed ID: 32620599 [TBL] [Abstract][Full Text] [Related]
9. Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study. Klepp P; Kisiel JB; Småstuen MC; Røseth A; Andersen SN; Vatn MH; Ahlquist DA; Moum BA; Brackmann S Scand J Gastroenterol; 2018 Mar; 53(3):273-278. PubMed ID: 29313389 [TBL] [Abstract][Full Text] [Related]
10. A novel multitarget stool DNA test for colorectal cancer screening. Malik P Postgrad Med; 2016; 128(2):268-72. PubMed ID: 26753807 [TBL] [Abstract][Full Text] [Related]
11. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?]. Quintero E Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340 [TBL] [Abstract][Full Text] [Related]
12. DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model. Baxter NT; Koumpouras CC; Rogers MA; Ruffin MT; Schloss PD Microbiome; 2016 Nov; 4(1):59. PubMed ID: 27842559 [TBL] [Abstract][Full Text] [Related]
13. Colorectal Cancer Screening: Stool DNA and Other Noninvasive Modalities. Bailey JR; Aggarwal A; Imperiale TF Gut Liver; 2016 Mar; 10(2):204-11. PubMed ID: 26934885 [TBL] [Abstract][Full Text] [Related]
14. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing. Berger BM; Parton MA; Levin B Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323 [TBL] [Abstract][Full Text] [Related]
15. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing. van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499 [TBL] [Abstract][Full Text] [Related]
16. Feasibility of quantification based on novel evaluation with stool DNA and fecal immunochemical test for colorectal cancer detection. Xu H; Chen H; Hu J; Xiong Z; Li D; Wang S; Yu J BMC Gastroenterol; 2022 Aug; 22(1):384. PubMed ID: 35963995 [TBL] [Abstract][Full Text] [Related]
17. Noninvasive fecal testing for colorectal cancer. Zou J; Xiao Z; Wu Y; Yang J; Cui N Clin Chim Acta; 2022 Jan; 524():123-131. PubMed ID: 34756863 [TBL] [Abstract][Full Text] [Related]
18. Multitarget stool DNA testing for colorectal-cancer screening. Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800 [TBL] [Abstract][Full Text] [Related]
19. Screening for colon cancer: A test for occult blood. Khakimov N; Khasanova G; Ershova K; Gibadullina L; Vetkina T; Lobisheva G; Chumakova A Int J Risk Saf Med; 2015; 27 Suppl 1():S110-1. PubMed ID: 26639687 [TBL] [Abstract][Full Text] [Related]
20. Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. Levin TR; Corley DA; Jensen CD; Marks AR; Zhao WK; Zebrowski AM; Quinn VP; Browne LW; Taylor WR; Ahlquist DA; Lidgard GP; Berger BM Dig Dis Sci; 2017 Mar; 62(3):678-688. PubMed ID: 28044229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]